Datopotamab administration methods, dosage frequency, and precautions

Datopotamab Deruxtecan is usually given as an intravenous infusion. Before infusion, medical staff will calculate the required dose based on the patient's weight and treatment plan, dilute it with the designated solvent and then infuse it slowly. The infusion time is generally controlled between 30 and 90 minutes to reduce the risk of infusion-related reactions. At the time of the first infusion, prophylactic medication (such as antihistamines and antipyretic analgesics) is usually given to reduce the occurrence of adverse effects.

Based on current clinical studies and marketing instructions, the recommended dose of Datopotamab is 6 mg/kg, usually administered every three weeks (21 days). Specific dosage may be adjusted based on individual patient circumstances, tolerance, and concomitant medications. The duration of treatment depends on the patient's response to and tolerance of treatment and is usually continued until disease progression or intolerable toxicity occurs.

During the treatment, if the patient experiences serious adverse reactions, such as hematological toxicity (neutropenia, thrombocytopenia) or non-hematological toxicity (such as interstitial lung disease) grade 3 or above, the drug should be suspended. After the patient's symptoms are relieved to an acceptable level, the drug can be resumed and the dosage appropriately reduced according to the doctor's judgment. In addition, for patients with hepatic and renal insufficiency, the risks of use should be carefully assessed, and the dose should be adjusted or the dosing interval extended if necessary.

When using Datopotamab, the patient's blood routine, liver and kidney function, and pulmonary symptoms need to be closely monitored. Pay special attention to early signs of adverse pulmonary reactions, such as coughing and dyspnea. Patients should be observed during and after the infusion so that infusion-related reactions can be detected and managed promptly. Pregnant and lactating women are prohibited from taking this medicine, and women of childbearing age should take effective contraceptive measures. To ensure safety, patients should use medications regularly under the guidance of a professional medical team.

Reference materials:https://www.fda.gov/drugs/